Trials / Completed
CompletedNCT04515550
Mitochondrial Biomarkers in Huntington's Disease
Longitudinal Biospecimen Collection for Mitochondrial Metabolomics in Huntington's Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 27 (actual)
- Sponsor
- University Hospitals Cleveland Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to discover a panel of mitochondrial metabolomics biomarkers for Huntington's disease.
Detailed description
This investigator-initiated, single-site longitudinal study seeks to assess the utility of mitochondrial metabolomics -- panels of small molecules that affect mitochondrial function -- to diagnose pre-symptomatic, pre-manifest, and symptomatic Huntington's disease and serve as biomarkers for HD severity and progression. It also seeks to demonstrate that this novel biomarker in the blood has comparable value to the same analysis in spinal fluid. This research study involves 3-4 visits over 18 months. Forty volunteers with HD and 25 volunteers without HD will be included. Volunteers who have HD will have a physical examination and blood draw at each study visit. Some participants will also volunteer for optional lumbar puncture.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | lumbar puncture | Some participants will have an optional lumbar puncture |
Timeline
- Start date
- 2019-04-04
- Primary completion
- 2022-02-28
- Completion
- 2022-02-28
- First posted
- 2020-08-17
- Last updated
- 2022-04-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04515550. Inclusion in this directory is not an endorsement.